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ABSTRACT
Objective: The objectives of this study were to assess the efficacy ofmedical management for vulvar
vestibulitis and to examine several historical variables and determine their predictive values as to
which treatments will be most successful.
Methods: Seventy-four patients diagnosed with vulvar vestibulitis were evaluated. Each patient
was treated using a sequence ofconsecutive medical therapies for vulvar vestibulitis. These therapies
were topical aqueous4% lidocaine with intercourse, topical corticosteroid therapy, oral amitriptyline,
topical low-dose 5-fluorouracil (5-FU) cream, intralesional alpha-interferon, and a low-oxalate diet
in combination with oral calcium citrate. The patients were followed over 3-30 months and their
responses to therapy were assessed. In addition, a statistical analysis was performed to determine
the positive predictive values of certain historical variables and specific treatment successes.
Results: Forty-nine patients reported positive responses to one of the initiated therapies. More
specifically, 18.1% of the patients who used lidocaine, 33.8% who used topical corticosteroids, 57.1%
who used amitriptyline, 16.7% who used 5-FU, none who received interferon, and 50% who tried
a low-oxalate diet had positive responses to therapy. No historical variables were predictive of
which therapies would have the most successful outcome.
Conclusions: Medical management is effective in alleviating the symptoms of vulvar vestibulitis.
Various aspects of a patient’s history are not helpful in selecting the therapy that will be most
effective. (C) 1996 Wiley-Liss, Inc.
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ulvar vestibulitis, a common cause of dyspareu-
nia in women, continues to be of unknown eti-
ology. This entity was first described by Skene in
1889 as "hyperesthesia" or "excessive sensitivity"
of the vulvar vestibule. He reported patients with
no external manifestations of disease who experi-
enced great pain with any contact with the sensitive
areas. In 1891, Thomas and Munde speculated that
women with this malady had "an excessive sensibil-
ity ofthe nerves supplying the mucous membranes"
of the vulvar vestibule. Kelly also attributed cases
of superficial localized dyspareunia to "sensitive
deep-red spots in the mucosa of the hymenal ring."
For almost 50 years, vulvar hyperesthesia was un-
mentioned in the medical literature. Peckham and
colleagues fully characterized "focal vulvitis," a
syndrome in which a patient history of persistent
vulvovaginal burning or discomfort is associated
with dyspareunia or the insertion of tampons. The
diagnostic criteria for this syndrome are as follows:
vulvar pain, dyspareunia, or pain with insertion of
tampons; one or more minute, exquisitely sensitive,
focal inflammatory lesions located in the vestibule;
and no identifiable cause such as herpes progeni-
talis, bacterial or candidal vaginitis, or pemphigoid.
In the past, surgical excision of the vestibule was
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the mainstay of therapy. A conservative stepwise
approach to vulvar vestibulitis utilizing topical lido-
caine and steroids, oral amitriptyline, low-oxalate
diet with oral calcium citrate, intralesional inter-
feron, and topical 5-fluorouracil (5-FU) cream was
developed as an alternative to what many patients
perceived as a radical approach to their disease. The
objective of this article is to detail our experience
with this approach. We sought to determine
whether historical variables such as the duration and
type of symptoms, history of documented human
papillomavirus (HPV) infection, history of antifun-
gal use, and positive fungal cultures could suggest
which therapy would be most likely to be effective.
SUBJECTS AND METHODS
From a cohort of an estimated 750 patients referred
for the evaluation of chronic vaginal symptoms to
the Temple University Vaginitis Referral Center,
74 patients diagnosed with vulvar vestibulitis were
identified. For each patient, a medical and sexual
history was taken with special attention paid to
the vaginal symptoms. The quality and severity
of symptoms with regard to dyspareunia, burning,
itching, swelling, and discharge were scored, and
the duration of the symptoms and the patient’s
age at the onset of her symptoms were recorded.
The symptoms were scored in the following man-
ner: absent 0, minimal 1, moderate 2, and
severe 3. For the statistical analysis, scores of 0
or were considered negative, and scores of 2 and
3 were counted as positive.
On the patient’s first presentation as well as at
subsequent follow-up visits, fungal cultures were
obtained from the vagina and vestibule and a micro-
scopic examination of the discharge with saline and
10% potassium hydroxide preparations was per-
formed. The patients with normal microscopic find-
ings who fulfilled the criteria for vulvar vestibulitis
were included in this analysis. Any patient with
fungal elements present on microscopy or with
positive yeast cultures was started on a 6-month
suppressive regimen of oral fluconazole, 200 mg
weekly. If a non-Candida albicans yeast was isolated,
a mycologic cure was achieved with boric-acid sup-
positories. If, 2 months after a sustained mycologic
cure, the patient still fulfilled the diagnostic criteria,
the treatment for vulvar vestibulitis was initiated.
Each patient was assigned to a sequential treat-
ment plan consisting ofone or more ofthe following
therapies: 1) avoidance of any external irritants and
the use of aqueous 4% lidocaine applied to the
vestibule prior to intercourse for month; 2) topical
0.25% desoximetasone cream applied twice daily
to the vestibule for month; 3) oral amitriptyline
started at a low dose and gradually increased to the
dose that alleviated the symptoms up to a max-
imum of 100 mg daily for 3 months; 4) topical
5-FU cream applied once weekly to the vestibule
for month; 5) injections with recombinant alpha-
interferon, 12 injections of 1 million units each in
a clockwise fashion to the vestibule over the course
of 4 weeks, followed by observation for another 4
weeks; and 6) a low-oxalate diet with calcium citrate
supplementation for up to 3 months according to
the protocol proposed by Solomons and colleagues,
Each patient was followed to assess the tolerance
and response to the therapy. A positive response to
therapy was recorded if the patient reported an
improvement or amelioration of the symptoms to
the extent that she was having few symptoms in her
daily activities and could have enjoyable intercourse
with minimal pain. A negative response was re-
corded if the therapy was not tolerated because of
side effects or if no improvement or worsening of
the symptoms was noted. Only one treatment mo-
dality was used at any given time.
A statistical analysis using the Epi Info statistical
software package (Centers for Disease Control, At-
lanta, GA) was carried out in order to assess whether
the duration of symptoms; positive yeast cultures;
history of HPV infection; prior antifungal use coin-
ciding with the onset of vulvar burning; or dysuria,
vaginal discharge, dyspareunia, itching, burning, or
swelling was associated with a favorable response
to a particular therapy. The categorical data were
analyzed for significance by means of the Mantel-
Haenszel chi-square formula. If a value of <5 was
encountered, a 2-tailed P value was obtained with
the Fisher exact test.
RESULTS
The mean patient age was 30.2 +__ 5.9 years. The
mean age at the onset of vaginal symptoms was
26.5 6.5 years. The mean duration of symptoms
was 42 +__ 42.6 months, with a range of 4-190
months. All but one patient were white. Forty-six
(62.2%) patients were nulligravid and 61 (82.4%)
patients were nulliparous.
The vaginal symptoms and responses to therapy
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TABLE I. Response to various therapies
Therapy
No. of patients
receiving therapy
No. of patients with
positive responses
to therapy
Lidocaine
Desoximetasone
Amitriptyline
5-FU
Alpha-interferon
Low-oxalate diet/calcium citrate
72 13 (18.1%)
68 23 (33.8%)
35 20 (57. I%)
6 I(16.7%)
4 2 (so%y
14 7 (50%)
Vestibulitis recurred in both patients.
were recorded and scored as previously indicated.
In 56 (75.7%) patients, the main symptom was dys-
pareunia. In terms of day-to-day symptoms, 24
(32.4%) patients noted significant itching, 49
(66.1%) burning, 24 (32.4%) swelling, 33 (44.6%) a
noticeable vaginal discharge, and 35 (47.3%) dys-
uria. Three of the 74 (4%) patients had biopsy-
proven interstitial cystitis.
Twenty-six (35.1%) patients had undergone vul-
var biopsies either by their referring gynecologists
or during the course of this study. All of the biopsy
specimens reported varying degrees of inflamma-
tion. Ten (38.5%) were suggestive of HPV infec-
tion; one showed eczematous dermatitis.
By the time the patients with vulvar vestibulitis
had been referred to us, 67 (90.5%) had had at least
one prior course of topical antimycotic therapy. Of
these, 33 (44.6%) reported that the onset of their
vaginal burning and dyspareunia coincided with the
use of this therapy. Despite repeated fungal cul-
tures at each visit, only 18 (24.3%) had a docu-
mented presence of yeast: 15 C. albicans, 2 C. parap-
silosis, and 1 Saccharomyces cerevisiae.
The time of follow-up was between 3 and 30
months (mean 18.23 + 7.0 months). The follow-
up was discontinued when a positive response was
achieved with a particular mode of therapy and the
patient felt that her symptoms had diminished to
an acceptable or a nonexistent level. The responses
to various therapies are presented in Table 1. Thir-
teen (18.1%) patients improved with lidocaine and
the removal of external irritants; however, 9 of these
women decided to attempt a trial of corticosteroids
to further improve their symptoms. Of the 20 pa-
tients who responded to amitriptyline, 10 required
a dose of 75 or 100 mg to respond. Although 2 of the
4 patients receiving interferon had initial positive
responses, both recurred with severe vestibulitis
within 3 months. These patients were scored as
failures. Overall, 49 (66.2%) of our cohort of 74
patients achieved an alleviation of their symptoms.
Of the remaining patients, 2 underwent vestibu-
lectomies with the complete resolution of their
symptoms. Three were, at their request, referred
elsewhere for laser surgery of the vestibule. The
remaining 20 patients were lost to follow-up or did
not wish to attempt further therapy.
A univariate analysis was used to determine if
certain historical factors were predictive of the re-
sponse to a particular therapy. A positive response
to therapy was not correlated with the duration of
symptoms, the concomitant presence of yeast, or
the presence of dysuria, dyspareunia, vulvar burn-
ing or itching, or vaginal discharge.
DISCUSSION
Vulvar vestibulitis remains a syndrome ofunknown
etiology. Biopsy specimens taken of the affected
areas of the vestibule usually show a nonspecific
chronic inflammatory infiltrate in the subepithelial
tissues which sometimes involves the ducts of the
minor vestibular glands. This finding may repre-
sent the endpoint of a number of pathologic pro-
cesses. The second most common pathologic find-
ing in vestibulitis is epithelial dysplasia with
koilocytotic atypia consistent with HPV infection.
However, according to Oakes, "There does not
appear to be a characteristic histological pattern in
focal vulvitis and certainly nothing which gives a
clue as to its causation."
The bladder, urethra, and vestibule are all de-
rived from the embryonic urogenital sinus. There-
fore, it has been postulated that a urogenital abnor-
mality or autoimmune disorder, with antibodies
directed toward the vulvar tissue, may account for
vestibulitis as well as interstitial cystitis. However,
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only 3 of our 74 patients had cystoscopic evidence
of interstitial cystitis in addition to vestibulitis.
A history of fungal infection is present in almost
all patients who present with vulvar vestibulitis.
However, it is impossible to know whether a pa-
tient’s vestibular symptoms are mistakenly treated
as a fungal infection when yeast are not truly present
or whether the vestibular symptoms indeed coin-
cide with or follow a real yeast infection. Ashman
and Ott proposed that antigens of C. albicans are
cross-reactive with certain vulvovaginal tissue anti-
gens which may account for the high association of
vestibulitis with a previous yeast infection. How-
ever, according to Marinoff and Turner,1 it is un-
likely that a delayed hypersensitivity reaction to
Candida or topical antifungal preparations is the
cause of vestibulitis. Despite these findings, it is
difficult to ignore the high incidence of vestibulitis
in women who associate the onset of their symp-
toms with the use of antifungals. Similarly, the rela-
tively high (24.3%) incidence of coexisting fungal
vaginitis in our patient population suggests that re-
current yeast infections may somehow play a role
in the initiation of this syndrome.
It has been postulated recently by Solomons et
al. that the pattern of pain associated with vestibu-
litis is related to urinary pH and urinary oxalate
excretion. Increased pain may be associated with
urinary pH values of 6.5-8.5 and transient hyperox-
aluria which can cause burning on contact with oxa-
late crystals or solution on vulvar mucosa. A low-
oxalate diet and calcium citrate supplementation
are thought to retard the nucleation and crystal
growth ofcalcium salts and decrease vestibular pain.
Of the patients who attempted this therapy, 50%
noted significant improvement. Interestingly, 3 in
the failure group stopped the therapy because they
were unable to tolerate either the diet or the calcium
citrate pills.
HPV has been suspected as a possible cause of
the vulvar vestibulitis syndrome. Turner and Mari-
nof11 studied 7 patients with vestibulitis who were
positive for HPV byDNA hybridization techniques.
The biopsies of these patients failed to show HPV
changes in all cases. They postulated that an inflam-
matory response around the superficial capillaries
may be the beginning of the body’s attempt to rid
itself of the virus. In later stages, there is dense
lymphocytic infiltration so that the typical histologic
features ofHPV may not be seen. The antiviral and
immunomodulatory action of alpha-interferon is
thought to be the mode of action in the treatment
of vestibulitis. The intralesional injection of recom-
binant alpha-interferon has been used in some stud-
ies with limited success. Marinoff et al.z found that
only 18% of the women they treated with interferon
showed substantial improvement (46/55 women
treated had HPV changes by vulvar biopsy) and the
response to interferon was not influenced by the
diagnosis of HPV. Our initial experience with inter-
feron therapy was also disappointing, and the dis-
comfort associated with this therapy led to our dis-
continuation of its use.
Among the more successful treatment modalities
has been the use of amitriptyline (or other tricyclic
antidepressants). This modality has been used in
the treatment of vulvodynia in which it is felt to
target the potential neurologic component of vulvar
pain and burning.
3 This neurologic component is
postulated to be a problem with cutaneous percep-
tion, either centrally or at the nerve root. Tricyclic
antidepressants have been used successfully to treat
glossodynia and postherpetic neuralgia, 2 forms of
cutaneous dysesthesia of which vulvar vestibulitis
may also be a member. Amitriptyline inhibits the
membrane pump mechanism responsible for the
uptake of norepinephrine and serotonin in adrener-
gic and serotonergic neurons which may potentiate
or prolong neuronal activity. This underlying mech-
anism is believed to be responsible for the antide-
pressant activity, although its true antidepressant
mechanism is unknown. In vulvodynia patients,
McKay
3 found the results of treatment with ami-
triptyline to be most successful in older women.
The success in treating vulvar vestibulitis with ami-
triptyline may be attributed to its effect on cutane-
ous nerve as well as its psychotropic effect. How-
ever, antidepressants have been shown to be
effective in treating many chronic pain syndromes
with or without the presence of depression. In this
study amitriptyline was the most successful medical
therapy, with a 55.9% response. The addition of
biofeedback therapy to this regimen may lead to
even better results.4
Surgical excision of the vestibule has been met
with some success in the treatment of vestibulitis.
Mann and colleagues
is reported a 66% success rate
and regression of symptoms following surgical exci-
sion by perineoplasty. However, concerns about the
cost, risks, and potential scarring frighten many
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women away from seeking therapy for their disease.
With an overall success rate of 66.2% in our study,
medical management offers an attractive alternative
to surgery. However, the relatively high number of
patients who were lost to follow-up or did not return
for further treatment underscores the downside of
a stepwise approach to management, namely the
need for more frequent office visits and what pa-
tients may perceive as very slow progress.
Vulvar vestibulitis is a chronic syndrome that
seems to respond to different therapies. In the pres-
ent study of 74 patients with vulvar vestibulitis, a
conservative medical approach was taken using the
previously mentioned modalities. The varying ef-
fectiveness of these r’egimens supports the use of
a stepwise protocol, starting with simple treatments
with few side effects. With such a protocol, many
women with vulvar vestibulitis can achieve ade-
quate relief of their symptoms with medical treat-
ment alone.
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